Ultima-Dbol 25 mg 50 Tablets Ultima Pharma USA
$109.00
Product Short Description
Ultima-Dbol 25 mg 50 Tablets Ultima Pharma USA delivers methandienone (C20H28O2), the 17α-methyl-Δ¹-testosterone derivative exhibiting rapid anabolic effects (~200:50-100 ratio), at 25 mg strength bridging prescription and institutional formats. Domestic U.S. production eliminates customs exposure serving DEA Schedule III compliant institutional channels through verified performance networks.
Product Overview
Ultima Pharma USA’s Dbol 25 mg presents methandienone (also known as metandienone), featuring C1,2 double bond modification conferring enhanced anabolic signaling with 17α-alkylation for oral bioavailability (~3-6 hour half-life), in round scored tablets designed for institutional catalog integration across DEA-registered platforms. The 50-tablet HDPE bottle configuration supports CIII-compliant inventory reconciliation under 21 CFR 1304.22, requiring detailed Schedule III tracking for institutional handlers maintaining federal compliance.
U.S.-domiciled GMP manufacturing upholds molecular specifications (MW 300.44) distinguishing legitimate Schedule III pedigree from underground powder conversions showing typical under-dosing. This intermediate-potency presentation serves institutional buyers needing Form 222 triplicate documentation across U.S. jurisdictions, avoiding international sourcing risks and grey-market authenticity issues.
Ultima-Dbol positions within verified DEA Schedule III ecosystems for licensed institutional clientele under 21 CFR 1301.13 registrant requirements, with strict commercial positioning excluding therapeutic claims or performance guidance.
Brand & Manufacturer Information
Ultima Pharma USA produces DEA Schedule III controlled substances via domestic GMP facilities serving institutional performance networks with DEA registrant verification. Dbol 25 mg fits Ultima’s progressive methandienone catalog (10→25→50 mg) authenticating supply chain legitimacy against powder-pressed alternatives rejected by institutional handlers.
Domestic warehousing enables Form 222 platforms without customs risk, with serialized batch documentation verifying 25 mg potency via HPLC assay, essential for institutional procurement.
Active Compound Information
Contains methandienone (methandrostenolone), a first-generation anabolic steroid with C1,2 diene unsaturation promoting protein synthesis, glycogenolysis, and nitrogen retention through androgen receptor activation. DEA Schedule III status reflects hepatotoxicity, estrogenic aromatization, and short half-life necessitating split dosing in performance contexts beyond discontinued medical uses.
25 mg strength serves as institutional escalation from historical 5-10 mg prescriptions while matching Δ¹ structure. Molecular formula C20H28O2; WADA S1.1a prohibited with sensitive detection.
Product Specifications
| Specification | Details |
|---|---|
| Product Name | Ultima-Dbol 25 mg 50 Tablets Ultima Pharma USA |
| Active Compound | Methandienone (C20H28O2) |
| Strength | 25 mg per round scored tablet |
| Quantity | 50 tablets per HDPE bottle |
| Form | Oral scored tablets |
| Category | DEA Schedule III controlled substance |
| Appearance | White, round, single-scored |
| Molecular Weight | 300.44 g/mol |
| Primary Packaging | Child-resistant HDPE bottle |
| Label Elements | “25 mg”, CIII warnings, serialized lot |
Quality Control & Testing Standards
25 mg methandienone requires USP <621> potency assay (HPLC 90-110%), USP <711> dissolution, USP <905> uniformity, and Δ¹-unsaturation verification confirming pharmaceutical standards. Ultima documentation verifies C20H28O2 identity distinguishing GMP production from underground sources.
50-tablet CIII packaging uses USP <671> HDPE barriers with child-resistant closure meeting 21 CFR 310.310(a). Stability follows ICH Q1A(R2) for 36-month shelf-life surpassing alternatives.
Intended Use & Market Positioning
Ultima-Dbol 25 mg targets DEA-registered CIII institutional researchers handling intermediate Schedule III anabolic inventories via encrypted fulfillment with Form 222 accountability. Serves verified institutional clientele exclusively.
No protocols, cycles, or outcomes represented in commercial CIII positioning.
Legal & Regulatory Disclaimer
Methandienone is DEA Schedule III under 21 USC §812; non-medical handling violates Controlled Substances Act (5 years/$250,000 penalties). Institutional buyers assume Form 222/DEA licensing liability; no medical claims provided.
MAECENAS IACULIS
Vestibulum curae torquent diam diam commodo parturient penatibus nunc dui adipiscing convallis bulum parturient suspendisse parturient a.Parturient in parturient scelerisque nibh lectus quam a natoque adipiscing a vestibulum hendrerit et pharetra fames nunc natoque dui.
ADIPISCING CONVALLIS BULUM
- Vestibulum penatibus nunc dui adipiscing convallis bulum parturient suspendisse.
- Abitur parturient praesent lectus quam a natoque adipiscing a vestibulum hendre.
- Diam parturient dictumst parturient scelerisque nibh lectus.
Scelerisque adipiscing bibendum sem vestibulum et in a a a purus lectus faucibus lobortis tincidunt purus lectus nisl class eros.Condimentum a et ullamcorper dictumst mus et tristique elementum nam inceptos hac parturient scelerisque vestibulum amet elit ut volutpat.
Reviews
There are no reviews yet.